The utilization of siRNA@PPDS micelles in the combined therapy targeting PD-L1-KD and HDACIs represents a potential and effective approach to overcome immune checkpoint inhibitor resistance and provide a promising treatment option for inhibiting tumor growth [93]. This evidence concerns the gene CD274 and neoplasm.